A 9-year-old spayed female Domestic Shorthair cat with a ...

Navigating chronic pain management in a feline patient with concurrent chronic kidney disease (CKD) requires a meticulous approach, as the very medications we rely on for pain relief can exacerbate renal compromise. It's a common and challenging scenario, and your careful consideration of renal toxicity is exactly right.

Here's my perspective on selecting the safest NSAID for your 9-year-old DSH with IRIS Stage 2 CKD and severe OA, along with strategies to minimize renal risk:

The Challenge of NSAIDs in CKD Cats

First, it's crucial to acknowledge that no NSAID is truly "safe" for long-term use in a cat with CKD. All NSAIDs inhibit cyclooxygenase (COX) enzymes, which are critical for producing prostaglandins that maintain renal blood flow, especially in compromised kidneys. Inhibiting these prostaglandins can lead to vasoconstriction of the afferent renal arteriole, reduced glomerular filtration rate (GFR), and acute kidney injury (AKI). This risk is amplified in dehydrated, hypotensive, or already renally impaired patients.

Safest NSAID to Consider: Robenacoxib (Onsior®)

If an NSAID is deemed absolutely necessary due to uncontrolled pain significantly impacting quality of life, robenacoxib (Onsior®) is generally considered the least risky option for cats, particularly for chronic use.

Why Robenacoxib?

Feline-Specific Approval: It is one of the few NSAIDs specifically approved for use in cats (for up to 6 days for acute pain and inflammation, or up to 28 days in Europe for chronic musculoskeletal pain). While chronic use beyond 28 days is off-label in the US, it has a better safety profile in cats than other NSAIDs.

Pharmacokinetics: Robenacoxib has a very short half-life in feline blood (approximately 1.7 hours), but it accumulates rapidly in inflammatory exudates, providing sustained local effect. Critically, it is predominantly eliminated via the hepatobiliary system (approximately 70% in cats), with minimal renal excretion (less than 1% as unchanged drug). This reduced reliance on renal clearance theoretically makes it a more favorable choice in CKD patients compared to drugs with significant renal excretion.

COX-2 Selectivity: While it is COX-2 preferential, this selectivity is not absolute and doesn't entirely mitigate renal risk, but it's generally considered less gastrotoxic than non-selective NSAIDs.

Dose Adjustments and Risk Mitigation Strategies

Given your cat's IRIS Stage 2 CKD, a standard NSAID protocol is inappropriate. Here’s how I would approach robenacoxib administration:

Thorough Pre-Treatment Assessment:

Hydration Status: Ensure the cat is well-hydrated before* initiating NSAID therapy. Administering subcutaneous fluids for 1-2 days prior can be beneficial.
* Renal Parameters: Obtain a current CBC, full chemistry panel (including BUN, creatinine, SDMA, phosphorus, potassium), and urinalysis (with specific gravity). Compare to previous values.
* Blood Pressure: Ensure blood pressure is well-controlled. Your cat is on amlodipine, which is good. NSAIDs can contribute to hypertension.
* Concurrent Medications: Review all medications. Gabapentin is excellent for neuropathic and chronic pain. Ensure no other nephrotoxic drugs are being used.

Initial Dosing and Trial Period:

* Robenacoxib: Start at the lower end of the recommended dose: 1 mg/kg PO daily for 3-5 days.
* Strict Observation: Monitor for any signs of adverse effects such as anorexia, lethargy, vomiting, diarrhea, or changes in thirst/urination.

CKD-Specific Dose Adjustment for Chronic Use:

If the initial trial period is tolerated without adverse effects and significant pain relief is observed, reduce the dosing frequency* for chronic management.
* Option A (Preferred): Administer 1 mg/kg PO every 48 hours (every other day).
* Option B (Alternative): Administer 1 mg/kg PO every 72 hours (every third day).
* Rationale: Rather than reducing the individual dose, which may fall below the therapeutic threshold, extending the interval maintains effective drug concentrations in inflamed tissues while giving the kidneys longer recovery periods between doses.

Intensive Monitoring:

* Short-Term: Recheck renal parameters (BUN, creatinine, SDMA, phosphorus, USG) and blood pressure within 5-7 days of initiating the reduced-frequency NSAID therapy.
* Long-Term: If stable, recheck these parameters every 2-4 weeks for the first 2-3 months, then every 1-3 months thereafter, or immediately if clinical signs of deterioration occur.
* Owner Education: Educate the owner thoroughly on potential signs of renal decompensation (increased thirst/urination, decreased appetite, lethargy, vomiting) and to discontinue the NSAID immediately and contact you if observed.

Multimodal Pain Management:

* NSAIDs should never be the sole pillar of chronic pain management in a CKD cat. Continue gabapentin.
* Consider adding other non-NSAID analgesics:
* Amantadine: An NMDA receptor antagonist that can help with chronic neuropathic pain and central sensitization. Dose: 3-5 mg/kg PO q24h.
* Environmental Modifications: Easy access to resources, soft bedding, ramps, gentle exercise.
* Weight Management: If overweight, weight loss can significantly reduce joint strain.
* Acupuncture/Laser Therapy: Can be very beneficial for OA pain in some cats.

NSAID to AVOID for Chronic Use in CKD Cats: Meloxicam (Metacam®)

While meloxicam is approved for a single subcutaneous injection in cats for surgical pain, its chronic oral use in cats is associated with a significantly higher risk of renal failure, particularly at doses used in dogs. The FDA has issued specific warnings against its chronic use in cats. Given the availability of robenacoxib and the known CKD, I would strongly advise against chronic meloxicam for this patient.

Conclusion

For your patient, robenacoxib (Onsior®) at 1 mg/kg PO every 48-72 hours, following a very short initial daily trial, is the most defensible NSAID choice. However, this decision must be made with the understanding that it carries inherent risks in a CKD patient. Rigorous pre-assessment, a highly conservative dosing strategy, and vigilant monitoring are absolutely critical. If pain can be managed effectively with gabapentin and other adjunctive therapies, avoiding an NSAID entirely remains the safest option for the kidneys.

High confidence – based on current evidence and clinical experience in feline internal medicine.